CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer - NCT04916002

Objective response rate (ORR) with CMP-001 in combination with a programmed cell death protein 1 (PD-1)-blocking antibody (cemiplimab-rwlc) in study subjects with metastatic or advanced/unresectable CSCC, MCC, or TNBC, Safety and tolerability of CMP-001 administered by intratumoral (IT) injection in combination with a PD-1-blocking antibody (cemiplimab-rwlc) in the study subjects, Efficacy of CMP-001 in combination with a PD-1-blocking antibody (cemiplimab-rwlc) in the study subjects